Cervix Regression and Motion During the Course of External Beam Chemoradiation for Cervical Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 73, Issue 1, 2009, Pages 235-241

  Beadle, Beth M ^a   Jhingran, Anuja ^a   Salehpour, Mohammad ^a   Sam, Marianne ^a   Iyer, Revathy B ^a   Eifel, Patricia J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cervical cancer; Cervix motion; IMRT; Radiation therapy; Tumor regression

Indexed keywords

COMPUTERIZED TOMOGRAPHY; DIAGNOSTIC RADIOGRAPHY; FLIGHT DYNAMICS; MEDICAL IMAGING; TOMOGRAPHY;

CERVICAL CANCER; CERVIX MOTION; IMRT; RADIATION THERAPY; TUMOR REGRESSION;

REGRESSION ANALYSIS;

CISPLATIN;

ARTICLE; BRACHYTHERAPY; CALCULATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SIZE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; MULTIPLE CYCLE TREATMENT; ORGAN SIZE; PRIORITY JOURNAL; RADIATION DOSE; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS; CERVIX UTERI; CISPLATIN; FEMALE; HUMANS; MOVEMENT; RADIOTHERAPY, CONFORMAL; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 57649107704     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.03.064     Document Type: Article

References (22)

1. Eifel P.J., Winter K., Morris M., et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: An update of Radiation Therapy Oncology Group trial (RTOG) 90-01. J Clin Oncol 22 (2004) 872-880
2. Whitney C.W., Sause W., Bundy B.N., et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 17 (1999) 1339-1348
3. Mell L.K., Mehrotra A.K., and Mundt A.J. Intensity-modulated radiation therapy use in the U.S., 2004. Cancer 104 (2005) 1296-1303
4. Brixey C.J., Roeske J.C., Lujan A.E., et al. Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys 54 (2002) 1388-1396
5. Mundt A.J., Roeske J.C., Lujan A.E., et al. Initial clinical experience with intensity-modulated whole-pelvis radiation therapy in women with gynecologic malignancies. Gynecol Oncol 82 (2001) 456-463
6. Salama J.K., Roeske J.C., Mehta N., et al. Intensity-modulated radiation therapy in gynecologic malignancies. Curr Treat Options Oncol 5 (2004) 97-108
7. Mundt A.J., Lujan A.E., Rotmensch J., et al. Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys 52 (2002) 1330-1337
8. Chan P., Yeo I., Perkins G., et al. Dosimetric comparison of intensity-modulated, conformal, and four-field pelvic radiotherapy boost plans for gynecologic cancer: A retrospective planning study. Radiat Oncol 1 (2006) 13
9. Schefter T.E., Kavanagh B.D., Wu Q., et al. Technical considerations in the application of intensity-modulated radiotherapy as a concomitant integrated boost for locally-advanced cervix cancer. Med Dosim 27 (2002) 177-184
10. Maintz J.B., and Viergever M.A. A survey of medical image registration. Med Image Anal 2 (1998) 1-36
11. Lee C.M., Shrieve D.C., and Gaffney D.K. Rapid involution and mobility of carcinoma of the cervix. Int J Radiat Oncol Biol Phys 58 (2004) 625-630
12. van de Bunt L., van der Heide U.A., Ketelaars M., et al. Conventional, conformal, and intensity-modulated radiation therapy treatment planning of external beam radiotherapy for cervical cancer: The impact of tumor regression. Int J Radiat Oncol Biol Phys 64 (2006) 189-196
13. Buchali A., Koswig S., Dinges S., et al. Impact of the filling status of the bladder and rectum on their integral dose distribution and the movement of the uterus in the treatment planning of gynaecological cancer. Radiother Oncol 52 (1999) 29-34
14. Jhingran A, Sam M, Salehpour M, et al. A pilot study to evaluate consistency of bladder filling and vaginal movement in patients receiving pelvic IMRT [abstract 113]. Presented at the 87th American Radium Society, Barcelona, Spain, April 30-May 4, 2005.
15. Portelance L., Chao K.S., Grigsby P.W., et al. Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation. Int J Radiat Oncol Biol Phys 51 (2001) 261-266
16. Lujan A.E., Mundt A.J., Yamada S.D., et al. Intensity-modulated radiotherapy as a means of reducing dose to bone marrow in gynecologic patients receiving whole pelvic radiotherapy. Int J Radiat Oncol Biol Phys 57 (2003) 516-521
17. Mundt A.J., Mell L.K., and Roeske J.C. Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy. Int J Radiat Oncol Biol Phys 56 (2003) 1354-1360
18. Chandra A., Dong L., Huang E., et al. Experience of ultrasound-based daily prostate localization. Int J Radiat Oncol Biol Phys 56 (2003) 436-447
19. Moseley D.J., White E.A., Wiltshire K.L., et al. Comparison of localization performance with implanted fiducial markers and cone-beam computed tomography for on-line image-guided radiotherapy of the prostate. Int J Radiat Oncol Biol Phys 67 (2007) 942-953
20. Ahamad A., D'Souza W., Salehpour M., et al. Intensity-modulated radiation therapy after hysterectomy: Comparison with conventional treatment and sensitivity of the normal-tissue-sparing effect to margin size. Int J Radiat Oncol Biol Phys 62 (2005) 1117-1124
21. Amendola M.A., Hricak H., Mitchell D.G., et al. Utilization of diagnostic studies in the pretreatment evaluation of invasive cervical cancer in the United States: Results of intergroup protocol ACRIN 6651/GOG 183. J Clin Oncol 23 (2005) 7454-7459
22. Mitchell D.G., Snyder B., Coakley F., et al. Early invasive cervical cancer: Tumor delineation by magnetic resonance imaging, computed tomography, and clinical examination, verified by pathologic results, in the ACRIN 6651/GOG 183 Intergroup Study. J Clin Oncol 24 (2006) 5687-5694